Transthyretin Amyloidosis Treatment Market, by Drug Type (Tafamidis (Vyndaqel), Patisiran (ONPATTRO), Inotersen (TEGSEDI), and Others), by Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, and Mixed) and Wild Type), and by Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Geography (North America, Latin America, Europe, Asia-Pacific, Middle East and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

  • Published On : Dec 2018 |
  • Pages : 221 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Global Transthyretin Amyloidosis Treatment Market – Insights

Hereditary transthyretin amyloidosis (hATTR) and wild type transthyretin amyloidosis are two main types of transthyretin amyloidosis. hATTR is further classified into Familial Amyloid Polyneuropathy (FAP) and Familial Amyloid Cardiomyopathy (FAC). Wild type variant (ATTRwt) predominantly affects the heart.

Transthyretin amyloidosis is a result of transthyretin produced by the liver and forms dimers, followed by monomers. Monomers aggregate to form amyloid fibrils, which are deposited in organs such as heart, nervous system, gastrointestinal tract, and kidneys. FAP is a subtype of hereditary transthyretin amyloidosis and the most common type of FAP is caused by the Val30Met variant of Transthyretin (TTR).

In familial amyloid polyneuropathy, the symptoms are first detected after the patient crosses 30 years of age, however, it can also be detected as early as 20 years or as late as 80 years of age. Symptoms are divided depending on the location such as peripheral neuropathy and autonomic neuropathy. Symptoms may worsen in case excess amyloid protein starts to collect in the nerves.

Introduction of novel therapy for the treatment of transthyretin amyloidosis is expected to significantly drive the market growth

Key players in the market are focused on approval and launch of novel therapies for treatment of transthyretin amyloidosis. This in turn is expected to propel growth of the global transthyretin amyloidosis treatment market over the forecast period.

For instance, in August 2018, Alnylam Pharmaceuticals, Inc. received the U.S. Food and Drug Administration (FDA) approval for its ONPATTRO (patisiran) lipid complex injection— a RNA interference (RNAi) therapeutic— indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

In July 2018, Ionis Pharmaceuticals, Inc. and Akcea Therapeutics, Inc. received marketing authorization approval for its drug TEGSEDI (inotersen) from the European Commission (EC) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis.

The global transthyretin amyloidosis treatment market size is expected to be valued at US$ 35.8 million in 2018 and is expected to witness a robust CAGR of 55.4% over the forecast period (2018–2026).

Figure 1. Global Transthyretin Amyloidosis Treatment Market Share (%), by Drug Type, 2018 and 2026

Transthyretin Amyloidosis Treatment  | Coherent Market Insights

                                                                            

Robust pipeline of transthyretin amyloidosis treatment drugs is expected to boost the market growth over the forecast period

Major players in the market have novel drugs in the pipeline, which are in late-stage clinical trials and are expected to receive approval in the near future. For instance, Eidos Therapeutics, Inc. is developing AG10— an orally-administered, small molecule designed to potently and selectively stabilize tetrameric TTR, thereby interfering with events that give rise to ATTR. The drug is currently in Phase 2 clinical trial.

Akcea Therapeutics Inc. is co-developing AKCEA-TTR- LRx with Ionis Pharmaceuticals to inhibit the production of transthyretin. Akcea Therapeutics Inc. is focused on developing AKCEA-TTR-LRx for patients with both hereditary and wild type form of the disease. AKCEA-TTR-LRx is planning to enter clinical development in 2018.                     

Figure 2. Global Transthyretin Amyloidosis Treatment Market Share (%), by Disease Type, 2018 and 2026

 Transthyretin Amyloidosis Treatment  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2017)

Key players in the market are focused on strategic partnerships in order to enhance their market share. For instance, in August 2018, Alnylam Pharmaceuticals, Inc. partnered with Orsini Healthcare, a specialty pharmacy as distributor of ONPATTRO (patisiran) lipid complex injection.

However, high costs of recently launched drugs is expected to hinder growth of the market. For instance, according to Alnylam Pharmaceutical, Inc., the cost of Patisiran is around US$ 450,000, annually before insurance. Another drug, Inotersen manufactured by Ionis Pharmaceuticals in partnership with Akcea Therapeutics, received approval for hereditary Transthyretin Amyloidosis Polyneuropathy indication and the drug costs US$ 450,000, annually. High cost of drugs may result in lower adoption even in developed economies such as the U.S., thereby restraining growth of the market.

 

Key players operating in the global transthyretin amyloidosis treatment market include, Alnylam Pharmaceuticals, Inc., Pfizer, Inc., Prothena Corporation Plc., GlaxoSmithKline Plc., Ionis Pharmaceuticals, Inc., Eidos Therapeutics, and SOM Innovation Biotech, S.L.

Transthyretin amyloidosis is a rare inherited and slowly progressive disease characterized by abnormal buildup of deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues. Two main type of transthyretin amyloidosis includes hereditary transthyretin amyloidosis and wild type transthyretin amyloidosis. Hereditary transthyretin amyloidosis is further divided into polyneuropathy, cardiomyopathy, and mixed type.

Diagnosis of transthyretin amyloidosis includes approaches such as imaging, histopathology, and molecular and genetic testing. Cardiac biomarkers such as N-terminal fragment of brain natriuretic peptide (NT-proBNP) and troponin are present in abnormally high concentrations in the heart, following amyloid deposits that can be tested for diagnosis of the disease. Genetic testing for transthyretin gene mutations is performed in case of familial transthyretin amyloidosis diagnosis.

Market Dynamics

Approvals and launches of novel therapies for the treatment of transthyretin amyloidosis is expected to be a major factor driving the market growth over the forecast period. In October 2018, Eidos Therapeutics, Inc. received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for its drug candidate AG10, indicated for the treatment of ATTR.

In October 2018, Ionis Pharmaceuticals, Inc. and its Akcea Therapeutics Inc., received approval for its drug TEGSEDITM (inotersen injection) in Canada for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR)

Furthermore, increasing number under development drugs for the treatment of transthyretin amyloidosis are expected to gain approval in the near future. Therefore, presence of such robust pipeline is expected to boost the market growth. For instance, GlaxoSmithKline plc. a pharmaceutical company, is developing dezamizumab (2398852)† +2315698†, a combination of GSK2398852 (anti-SAP mAb) and GSK2315698 (CPHPC) for the treatment of amyloidosis. Currently, the product is under phase 2 clinical trial.

Key features of the study:

  • This report provides in-depth analysis of the global transthyretin amyloidosis treatment market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018–2026)
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the global transthyretin amyloidosis treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key companies covered as a part of this study include, Alnylam Pharmaceuticals, Inc., Pfizer, Inc., Prothena Corporation Plc., GlaxoSmithKline Plc., Ionis Pharmaceuticals, Inc., Eidos Therapeutics, and SOM Innovation Biotech, S.L.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global transthyretin amyloidosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global transthyretin amyloidosis treatment market

Detailed Segmentation:

  • Global Transthyretin Amyloidosis Treatment Market, by Drug Type:
    • Tafamidis (Vyndaqel)
    • Patisiran (ONPATTRO)
    • Inotersen (TEGSEDI)
    • Others
  • Global Transthyretin Amyloidosis Treatment Market, by Disease Type:
    • Hereditary Transthyretin Amyloidosis
      • Polyneuropathy
      • Cardiomyopathy
      • Mixed Type
    • Wild Type Amyloidosis
  • Global Transthyretin Amyloidosis Treatment Market, by Distribution Channel:
    • Hospital Pharmacies
    • Specialty Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Transthyretin Amyloidosis Treatment Market, By Geography:
    • North America
      • By Drug Type:
        • Tafamidis (Vyndaqel)
        • Patisiran (ONPATTRO)
        • Inotersen (TEGSEDI)
        • Others
      • By Disease Type:
        • Hereditary Transthyretin Amyloidosis
          • Polyneuropathy
          • Cardiomyopathy
          • Mixed Type
        • Wild Type Amyloidosis
      • By Distribution Channel:
        • Hospital Pharmacies
        • Specialty Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Drug Type:
        • Tafamidis (Vyndaqel)
        • Patisiran (ONPATTRO)
        • Inotersen (TEGSEDI)
        • Others
      • By Disease Type:
        • Hereditary Transthyretin Amyloidosis
          • Polyneuropathy
          • Cardiomyopathy
          • Mixed Type
        • Wild Type Amyloidosis
      • By Distribution Channel:
        • Hospital Pharmacies
        • Specialty Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Type:
        • Tafamidis (Vyndaqel)
        • Patisiran (ONPATTRO)
        • Inotersen (TEGSEDI)
        • Others
      • By Disease Type:
        • Hereditary Transthyretin Amyloidosis
          • Polyneuropathy
          • Cardiomyopathy
          • Mixed Type
        • Wild Type Amyloidosis
      • By Distribution Channel:
        • Hospital Pharmacies
        • Specialty Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Drug Type:
        • Tafamidis (Vyndaqel)
        • Patisiran (ONPATTRO)
        • Inotersen (TEGSEDI)
        • Others
      • By Disease Type:
        • Hereditary Transthyretin Amyloidosis
        • Wild Type Amyloidosis
      • By Distribution Channel:
        • Hospital Pharmacies
        • Specialty Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • By Drug Type:
        • Tafamidis (Vyndaqel)
        • Patisiran (ONPATTRO)
        • Inotersen (TEGSEDI)
        • Others
      • By Disease Type:
        • Hereditary Transthyretin Amyloidosis
          • Polyneuropathy
          • Cardiomyopathy
          • Mixed Type
        • Wild Type Amyloidosis
      • By Distribution Channel:
        • Hospital Pharmacies
        • Specialty Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Type:
        • Tafamidis (Vyndaqel)
        • Patisiran (ONPATTRO)
        • Inotersen (TEGSEDI)
        • Others
      • By Disease Type:
        • Hereditary Transthyretin Amyloidosis
        • Wild Type Amyloidosis
      • By Distribution Channel:
        • Hospital Pharmacies
        • Specialty Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Central Africa
        • South Africa
        • North Africa
    • North Africa
  • Company Profiles
    • Alnylam Pharmaceuticals, Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Ionis Pharmaceuticals, Inc.
    • Pfizer, Inc.
    • Eidos Therapeutics, Inc.
    • Akcea Therapeutics, Inc.
    • Prothena Corporation Plc.
    • GlaxoSmithKline Plc.
    • SOM Innovation Biotech, S.L.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Disease Type
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Geography
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Clinical Characteristics
    • Disease Diagnosis
    • Treatment Overview
    • Mechanism Of Action
    • Pipeline Analysis
    • Product Approval/Launches
    • Partnership- Collaboration Scenario
    • Epidemiology
    • Pest Analysis
    • Porter’s Five Forces Analysis
    • Drivers
    • Restraints
    • Market Opportunities
  4. Global Transthyretin Amyloidosis Treatment Market, By Drug Type, 2016–2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017–2026
      • Segment Trends
    • Tafamidis (Vyndaqel)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
    • Patisiran (ONPATTRO)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
    • Inotersen (TEGSEDI)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
  5. Global Transthyretin Amyloidosis Treatment Market, By Disease Type, 2016–2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017–2026
      • Segment Trends
    • Hereditary Transthyretin Amyloidosis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
        • Polyneuropathy
        • Cardiomyopathy
        • Mixed Type
    • Wild Type Amyloidosis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
  6. Global Transthyretin Amyloidosis Treatment Market, By Distribution Channel, 2016–2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017–2026
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
    • Specialty Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
  7. Global Transthyretin Amyloidosis Treatment Market, By Geography, 2016 – 2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, By Geography, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, For Geography, 2017–2026
    • North America
      • Market Size and Forecast, By Drug Type, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Drug Type, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Type, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Drug Type, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Drug Type, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
        • Central Africa
        • South Africa
        • North Africa
    • Middle East
      • Market Size and Forecast, By Drug Type, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
        • GCC
        • Israel
      • Rest of Middle East
  8. Competitive Landscape
    • Company Profiles
      • Alnylam Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Ionis Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Eidos Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Akcea Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Prothena Corporation Plc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • GlaxoSmithKline Plc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • SOM Innovation Biotech, S.L.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  9. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 35 market data tables and 43 figures on "Transthyretin Amyloidosis Treatment Market – Global forecast to 2026”.

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.